Submitted by Anonymous (not verified) on 18 September 2026 - 11:05
Human medicines European public assessment report (EPAR): Adcomfo, omalizumab, Status: Opinion
Source:
Human medicines European public assessment report (EPAR): Adcomfo, omalizumab, Status: Opinion